101. Hypotony and the Argus II retinal prosthesis: causes, prevention and management
- Author
-
Raymond Iezzi, K. Thiran Jayasundera, Lejla Vajzovic, Jean-François Korobelnik, Alex Yuan, Lisa C. Olmos de Koo, David Gaucher, Laura Cinelli, Aleksandra Rachitskaya, Robert J. Greenberg, Daniela Bacherini, Albert J. Augustin, Peter Wiedemann, Marie Noelle Delyfer, Pierre Olivier Barale, Ninel Z. Gregori, Jennifer I. Lim, Paulo E. Stanga, Robert G. Devenyi, Mark S. Humayun, Sarah Ayello-Scheer, Suber S. Huang, Peter Walter, J. Fernando Arevalo, Flavio A. Rezende, Allen C. Ho, Francesco Merlini, Paul Hahn, Emin Özmert, Dara D. Koozekanani, Lyndon da Cruz, Uday Patel, David N. Zacks, Sandra R. Montezuma, Sally Justus, Bernd Kirchhof, James T. Handa, Stanislao Rizzo, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Virulence bactérienne précoce : fonctions cellulaires et contrôle de l'infection aiguë et subaiguë, and Université de Strasbourg (UNISTRA)
- Subjects
Pars plana ,medicine.medical_specialty ,genetic structures ,Usher syndrome ,retinal prosthesis ,Ocular Hypotension ,epiretinal implant ,Blindness ,Choroideremia ,LEHA ,Prosthesis Implantation ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,0302 clinical medicine ,Eye Injuries ,Ophthalmology ,Retinitis pigmentosa ,Electrode array ,medicine ,Humans ,Intraocular Pressure ,Retrospective Studies ,Wound Healing ,outer retinal degenerative diseases ,business.industry ,Settore MED/30 - MALATTIE APPARATO VISIVO ,Incidence ,Ciliary Body ,Retinal ,hypotony ,medicine.disease ,eye diseases ,Sensory Systems ,Electrodes, Implanted ,Visual Prosthesis ,medicine.anatomical_structure ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,chemistry ,Retinal Prosthesis ,030221 ophthalmology & optometry ,Sclerostomy ,sense organs ,Implant ,business ,030217 neurology & neurosurgery ,Retinitis Pigmentosa - Abstract
The Argus II retinal prosthesis (Second Sight Medical Products, Sylmar, CA, USA) is an electronic epiretinal implant designed for use in patients with end-stage retinitis pigmentosa, as well as for other outer retinal degenerative conditions, such as choroideremia, Leber’s congenital amaurosis, Bardet-Biedl syndrome, Usher syndrome and rod–cone disease.1 This device was tested in a clinical trial of 30 subjects in the USA and in Europe to measure the rate of serious adverse events (SAEs) and to assess its effects on functional vision and visual acuity.2–4 Subjects performed better on visual tasks with the device turned on and retained these improvements at 5 years postsurgery.4 Additionally, an acceptable safety profile enabled approval of the device for consumer use by the European regulatory authorities in 2011 (Conformite Europeenne (CE) mark) and by the US Food and Drug Administration (FDA) in 2013 (FDA approval). The implant is composed of an extraocular component, namely, an electronics case and implant coil, as well as an intraocular component involving a 60-electrode array that is tacked over the macula (figure 1). The extraocular and intraocular components are connected by a trans-scleral silicone-coated polyamide electrode cable, and the implantation procedure involves a 5.2 mm pars plana sclerotomy incision to insert the electrode array and the electrode cable into the eye. The sclerotomy is then sutured around the cable and covered by an allograft or autograft material.5 Figure 1 The Argus II retinal prosthesis. Labelled image of the Argus II implant (adapted from Humayun et al 2). As with any system having both intraocular and extraocular components, the trans-scleral electrode cable that traverses the sclerotomy permanently is a high-risk feature of the device, as leakage through the pars plana incision can result in chronic hypotony. The percentages of clinical trial subjects who experienced hypotony were 10.0% at …
- Published
- 2019